Related Experiment Video
Updated: Jul 16, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Predictors of All-Cause Mortality After Successful Transcatheter Aortic Valve Implantation in Patients With Atrial
Masanori Yamamoto1, Kentaro Hayashida2, Christian Hengstenberg3
1Department of Cardiology, Toyohashi Heart Center, Aichi, Japan.
Insights
Predictors of long-term mortality after transcatheter aortic valve implantation (TAVI) in atrial fibrillation patients include age, renal function, and heart failure. Improved risk models enhance patient prognosis following TAVI.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Clinical Epidemiology
Background:
- Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve implantation (TAVI).
- AF is associated with worse outcomes and increased mortality after TAVI.
- Predicting long-term mortality in these patients is crucial for improving prognosis.
Purpose of the Study:
- To identify predictors of long-term all-cause mortality in patients with AF after successful TAVI.
- To evaluate the performance of a new risk prediction model compared to existing scores.
Main Methods:
- Analysis of data from the multicenter, prospective ENVISAGE-TAVI AF randomized controlled trial.
- A Cox proportional hazard model with a stepwise approach was used to identify mortality predictors.
- Performance assessment of the developed model and established risk scores (STS, CHA2DS2-VASc, HAS-BLED) using concordance statistics (c-statistic).
Main Results:
- 178 out of 1,426 patients (12.5%) died during a median follow-up of 548 days.
- Key mortality predictors identified: older age, impaired renal function, nonparoxysmal AF, excessive alcohol use, NYHA class III/IV heart failure, peripheral artery disease, and history of bleeding.
- The novel model (c-statistic 0.67) demonstrated superior discrimination compared to STS (0.56), CHA2DS2-VASc (0.54), and HAS-BLED (0.58) scores.
Conclusions:
- Several modifiable and nonmodifiable clinical factors significantly predict long-term mortality post-TAVI in AF patients.
- The developed risk stratification model shows improved accuracy in predicting mortality.
- Enhanced risk assessment can potentially improve long-term outcomes for TAVI patients with AF.
Abstract:
Prevalent and incident atrial fibrillation are common in patients who undergo transcatheter aortic valve implantation and are associated with impaired postprocedural outcomes, including mortality. We determined predictors of long-term mortality in patients with atrial fibrillation after successful transcatheter aortic valve implantation. The EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation-Atrial Fibrillation (ENVISAGE-TAVI AF) trial (NCT02943785) was a multicenter, prospective, randomized controlled trial in patients with prevalent or incident atrial fibrillation after successful transcatheter aortic valve implantation who received edoxaban or vitamin K antagonists. A Cox proportional hazard model was performed to identify predictors of all-cause mortality using a stepwise approach for multiple regression analysis. In addition, we assessed the performance of different risk scores and prediction models using ENVISAGE-TAVI AF data. Of 1,426 patients in ENVISAGE-TAVI AF, 178 (12.5%) died during the follow-up period (median 548 days). Our stepwise approach identified greater risk of mortality with older age, impaired renal function, nonparoxysmal atrial fibrillation, excessive alcohol use, New York Heart Association heart failure class III/IV, peripheral artery disease, and history of major bleeding or predisposition to bleeding. The present model (concordance statistic [c-statistic] 0.67) was a better discriminator than were other frequently used risk scores, such as the Society of Thoracic Surgeons score (c-statistic 0.56); Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke, Vascular disease, Age 65 to 74 years, and Sex category (CHA2DS2-VASc) score (c-statistic 0.54); or Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly, and Drugs/alcohol concomitantly (HAS-BLED) score (c-statistic 0.58). In ENVISAGE-TAVI AF, several modifiable and nonmodifiable clinical characteristics were significantly associated with greater long-term all-cause mortality. Improved risk stratification to estimate the probability of mortality after successful transcatheter aortic valve implantation in patients with atrial fibrillation may improve long-term patient prognosis.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Aneurysm IV: Nursing Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests

